[\/vc_column_text][vc_empty_space height=”20px”][vc_column_text el_class=”funding-text”]<\/p>\n
Our Sole Mission:<\/strong><\/h3>\n[\/vc_column_text][vc_column_text el_class=”funding-text”]<\/p>\n
Providing Risk Capital, Expertise, Resources and<\/strong>
\nGlobal Reach for Accelerated Clinical Development<\/strong><\/h3>\n[\/vc_column_text][vc_empty_space height=”80px”][vc_column_text el_class=”funding-text”]<\/p>\n
The SFJ Solution:<\/strong><\/h3>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”grid” text_align=”left” css_animation=”” el_class=”strategic-funding-section-box multiply-section” el_id=”divToShowHide”][vc_column_inner el_class=”faq-tab capital-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669572566{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”capital” el_id=”capital-blue-box”]<\/p>\n
Capital<\/h2>\n![\"\"](\"https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2020\/12\/mouse-pointer-1.png\")
<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1627536833709{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box capital-box box-hide” el_id=”solutions-capitals-box”]<\/p>\n
\n- Fund Trials (100%)<\/strong><\/li>\n
- Avoid Dilution<\/strong><\/li>\n
- Execute Large Deals<\/strong><\/li>\n
- Bridge To Readouts<\/strong><\/li>\n
- An Abingworth & Blackstone Company<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab expertise-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669659530{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”expertise” el_id=”expertise-blue-box”]<\/p>\n
Expertise<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1620882992216{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box expertise-box box-hide” el_id=”solutions-expertise-box”]<\/p>\n
\n- Multiple Approvals<\/strong><\/li>\n
- US \/ Japan \/ China \/ EU<\/strong><\/li>\n
- Trial Design<\/strong><\/li>\n
- Trial Execution<\/strong><\/li>\n
- World-Class Advisors<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab resources-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669760758{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”resources” el_id=”resources-blue-box”]<\/p>\n
Resources<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625220589763{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box resources-box box-hide” el_id=”solutions-resources-box”]<\/p>\n
\n- Global Reach<\/strong><\/li>\n
- Multiple Disciplines<\/strong><\/li>\n
- Incremental Headcount<\/strong><\/li>\n
- CRO Management<\/strong><\/li>\n
- Full Service<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab pipeline-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1625220577090{padding-top: 4px !important;padding-bottom: 3px !important;background-color: #001e3c !important;}” el_class=”pipeline” el_id=”pipeline-blue-box”]<\/p>\n
Pipeline \/ Asset Acceleration<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625220681454{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box pipeline-box box-hide” el_id=”solutions-pipeline-box”]<\/p>\n
\n- New Indications<\/strong><\/li>\n
- Incremental Assets<\/strong><\/li>\n
- In-Licensing \/ M&A Support<\/strong><\/li>\n
- Augmented Trial Budget<\/strong><\/li>\n
- Parallel Trials (vs. Sequential)<\/strong><\/li>\n
- Ex-US Approvals<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1628682735405{background: #ffffff url(https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2021\/05\/SFJ-by-the-numbers.jpg?id=8623) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” z_index=”” el_class=”sfj-numbers” background_image=”8154″][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_empty_space height=”20px”][\/vc_column_inner][\/vc_row_inner][vc_single_image image=”10788″ img_size=”full” alignment=”center” qode_css_animation=””][vc_empty_space height=”40px”][vc_empty_space height=”40px” el_class=”empty-space-home”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][qode_elements_holder number_of_columns=”two_columns” columns_proportion=”25_75″ switch_to_one_column=”never” alignment_one_column=”left”][qode_elements_holder_item vertical_alignment=”middle” horizontal_alignment=”center” advanced_animations=”no” item_padding=”0px 5px 0px 0px”][vc_single_image image=”11208″ img_size=”150 x 68″ alignment=”center” qode_css_animation=””][\/qode_elements_holder_item][qode_elements_holder_item vertical_alignment=”middle” advanced_animations=”no” custom_class=”sfj-bracket-text-right”][vc_column_text]<\/p>\n
\n- Fills operational and funding gaps<\/li>\n
- Provides bridge to increased ex-U.S. value<\/li>\n
- Assumes 100% of clinical development risk<\/li>\n
- Augments expertise<\/li>\n
- Accelerates follow-on indications<\/li>\n
- Tailors payback to financial objectives<\/li>\n<\/ul>\n
[\/vc_column_text][\/qode_elements_holder_item][\/qode_elements_holder][vc_empty_space height=”40px” el_class=”empty-space-home”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1625602041936{background-color: #ffffff !important;}” z_index=”” el_class=”sfj-numbers” background_image=”8154″][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]<\/p>\n
SFJ By The Numbers:<\/h2>\n
[\/vc_column_text][vc_separator type=”small” position=”center” width_in_percentages=”yes” color=”#fd5020″ transparency=”1″ thickness=”6″ width=”30″ up=”22″ down=”22″][vc_empty_space height=”40px”][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”” el_class=”sfj-numbers”][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Total Deal
\nValue<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
$4.5 billion<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Total # of
\nPartnerships<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
11<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
# of Oncology Partnerships<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
6<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Year
\nFounded<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
2009<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Major Market Approvals<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
17<\/h3>\n
[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”40px”][vc_empty_space height=”40px”][vc_row_inner row_type=”row” type=”grid” text_align=”center” css_animation=”” el_class=”mpb”][vc_column_inner el_class=”hide-col-btn” width=”1\/6″][\/vc_column_inner][vc_column_inner el_class=”bracket-top” width=”2\/3″ css=”.vc_custom_1629868834725{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column_text el_class=”bracket-bottom” css=”.vc_custom_1625154729407{padding-right: 30px !important;padding-bottom: 30px !important;padding-left: 30px !important;}”]<\/p>\n
\u201cSFJ has proven to be a collaborative and transparent partner from the start of our partnership.\u00a0 Their team is extremely knowledgeable, and add immense value well beyond the financial aspect.\u00a0 SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.\u201d<\/em><\/p>\n <\/p>\n
\u2014 Cedric Francois, CEO<\/strong>
\nApellis Pharmaceuticals<\/p>\n[\/vc_column_text][vc_empty_space height=”40px” el_class=”empty-space-home”][\/vc_column_inner][vc_column_inner el_class=”hide-col-btn” width=”1\/6″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”center” background_image_as_pattern=”without_pattern” css=”.vc_custom_1629891940309{background: #ffffff url(https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2020\/12\/bg-image-2.jpg?id=1168) !important;}” z_index=”” el_class=”primary-investors”][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]<\/p>\n
Primary Investors<\/h2>\n
[\/vc_column_text][vc_separator type=”small” position=”center” width_in_percentages=”yes” color=”#fd5020″ transparency=”1″ thickness=”6″ width=”30″ up=”22″ down=”22″][vc_empty_space height=”40px”][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”grid” text_align=”center” css_animation=””][vc_column_inner width=”1\/4″][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_single_image image=”1133″ img_size=”full” style=”vc_box_shadow” onclick=”custom_link” img_link_target=”_blank” qode_css_animation=”” link=”https:\/\/www.blackstone.com”][vc_empty_space height=”20px”][vc_column_text]<\/p>\n
Over $800 Billion<\/h2>\n
Assets Under Management<\/strong><\/p>\n[\/vc_column_text][vc_empty_space height=”10px”][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_single_image image=”1213″ img_size=”full” style=”vc_box_shadow” onclick=”custom_link” img_link_target=”_blank” qode_css_animation=”” link=”https:\/\/www.abingworth.com” el_class=”mpb”][vc_empty_space height=”20px”][vc_column_text]<\/p>\n
$2.5 Billion<\/h2>\n
Raised in Life Science Funds<\/strong><\/p>\n
\nGlobal Reach for Accelerated Clinical Development<\/strong><\/h3>\n
[\/vc_column_text][vc_empty_space height=”80px”][vc_column_text el_class=”funding-text”]<\/p>\n
The SFJ Solution:<\/strong><\/h3>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”grid” text_align=”left” css_animation=”” el_class=”strategic-funding-section-box multiply-section” el_id=”divToShowHide”][vc_column_inner el_class=”faq-tab capital-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669572566{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”capital” el_id=”capital-blue-box”]<\/p>\n
Capital<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1627536833709{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box capital-box box-hide” el_id=”solutions-capitals-box”]<\/p>\n
\n- Fund Trials (100%)<\/strong><\/li>\n
- Avoid Dilution<\/strong><\/li>\n
- Execute Large Deals<\/strong><\/li>\n
- Bridge To Readouts<\/strong><\/li>\n
- An Abingworth & Blackstone Company<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab expertise-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669659530{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”expertise” el_id=”expertise-blue-box”]<\/p>\n
Expertise<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1620882992216{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box expertise-box box-hide” el_id=”solutions-expertise-box”]<\/p>\n
\n- Multiple Approvals<\/strong><\/li>\n
- US \/ Japan \/ China \/ EU<\/strong><\/li>\n
- Trial Design<\/strong><\/li>\n
- Trial Execution<\/strong><\/li>\n
- World-Class Advisors<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab resources-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669760758{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”resources” el_id=”resources-blue-box”]<\/p>\n
Resources<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625220589763{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box resources-box box-hide” el_id=”solutions-resources-box”]<\/p>\n
\n- Global Reach<\/strong><\/li>\n
- Multiple Disciplines<\/strong><\/li>\n
- Incremental Headcount<\/strong><\/li>\n
- CRO Management<\/strong><\/li>\n
- Full Service<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab pipeline-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1625220577090{padding-top: 4px !important;padding-bottom: 3px !important;background-color: #001e3c !important;}” el_class=”pipeline” el_id=”pipeline-blue-box”]<\/p>\n
Pipeline \/ Asset Acceleration<\/h2>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625220681454{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box pipeline-box box-hide” el_id=”solutions-pipeline-box”]<\/p>\n
\n- New Indications<\/strong><\/li>\n
- Incremental Assets<\/strong><\/li>\n
- In-Licensing \/ M&A Support<\/strong><\/li>\n
- Augmented Trial Budget<\/strong><\/li>\n
- Parallel Trials (vs. Sequential)<\/strong><\/li>\n
- Ex-US Approvals<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1628682735405{background: #ffffff url(https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2021\/05\/SFJ-by-the-numbers.jpg?id=8623) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” z_index=”” el_class=”sfj-numbers” background_image=”8154″][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_empty_space height=”20px”][\/vc_column_inner][\/vc_row_inner][vc_single_image image=”10788″ img_size=”full” alignment=”center” qode_css_animation=””][vc_empty_space height=”40px”][vc_empty_space height=”40px” el_class=”empty-space-home”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][qode_elements_holder number_of_columns=”two_columns” columns_proportion=”25_75″ switch_to_one_column=”never” alignment_one_column=”left”][qode_elements_holder_item vertical_alignment=”middle” horizontal_alignment=”center” advanced_animations=”no” item_padding=”0px 5px 0px 0px”][vc_single_image image=”11208″ img_size=”150 x 68″ alignment=”center” qode_css_animation=””][\/qode_elements_holder_item][qode_elements_holder_item vertical_alignment=”middle” advanced_animations=”no” custom_class=”sfj-bracket-text-right”][vc_column_text]<\/p>\n
\n- Fills operational and funding gaps<\/li>\n
- Provides bridge to increased ex-U.S. value<\/li>\n
- Assumes 100% of clinical development risk<\/li>\n
- Augments expertise<\/li>\n
- Accelerates follow-on indications<\/li>\n
- Tailors payback to financial objectives<\/li>\n<\/ul>\n
[\/vc_column_text][\/qode_elements_holder_item][\/qode_elements_holder][vc_empty_space height=”40px” el_class=”empty-space-home”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1625602041936{background-color: #ffffff !important;}” z_index=”” el_class=”sfj-numbers” background_image=”8154″][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]<\/p>\n
SFJ By The Numbers:<\/h2>\n
[\/vc_column_text][vc_separator type=”small” position=”center” width_in_percentages=”yes” color=”#fd5020″ transparency=”1″ thickness=”6″ width=”30″ up=”22″ down=”22″][vc_empty_space height=”40px”][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”” el_class=”sfj-numbers”][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Total Deal
\nValue<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
$4.5 billion<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Total # of
\nPartnerships<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
11<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
# of Oncology Partnerships<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
6<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Year
\nFounded<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
2009<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Major Market Approvals<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
17<\/h3>\n
[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”40px”][vc_empty_space height=”40px”][vc_row_inner row_type=”row” type=”grid” text_align=”center” css_animation=”” el_class=”mpb”][vc_column_inner el_class=”hide-col-btn” width=”1\/6″][\/vc_column_inner][vc_column_inner el_class=”bracket-top” width=”2\/3″ css=”.vc_custom_1629868834725{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column_text el_class=”bracket-bottom” css=”.vc_custom_1625154729407{padding-right: 30px !important;padding-bottom: 30px !important;padding-left: 30px !important;}”]<\/p>\n
\u201cSFJ has proven to be a collaborative and transparent partner from the start of our partnership.\u00a0 Their team is extremely knowledgeable, and add immense value well beyond the financial aspect.\u00a0 SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.\u201d<\/em><\/p>\n <\/p>\n
\u2014 Cedric Francois, CEO<\/strong>
\nApellis Pharmaceuticals<\/p>\n[\/vc_column_text][vc_empty_space height=”40px” el_class=”empty-space-home”][\/vc_column_inner][vc_column_inner el_class=”hide-col-btn” width=”1\/6″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”center” background_image_as_pattern=”without_pattern” css=”.vc_custom_1629891940309{background: #ffffff url(https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2020\/12\/bg-image-2.jpg?id=1168) !important;}” z_index=”” el_class=”primary-investors”][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]<\/p>\n
Primary Investors<\/h2>\n
[\/vc_column_text][vc_separator type=”small” position=”center” width_in_percentages=”yes” color=”#fd5020″ transparency=”1″ thickness=”6″ width=”30″ up=”22″ down=”22″][vc_empty_space height=”40px”][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”grid” text_align=”center” css_animation=””][vc_column_inner width=”1\/4″][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_single_image image=”1133″ img_size=”full” style=”vc_box_shadow” onclick=”custom_link” img_link_target=”_blank” qode_css_animation=”” link=”https:\/\/www.blackstone.com”][vc_empty_space height=”20px”][vc_column_text]<\/p>\n
Over $800 Billion<\/h2>\n
Assets Under Management<\/strong><\/p>\n[\/vc_column_text][vc_empty_space height=”10px”][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_single_image image=”1213″ img_size=”full” style=”vc_box_shadow” onclick=”custom_link” img_link_target=”_blank” qode_css_animation=”” link=”https:\/\/www.abingworth.com” el_class=”mpb”][vc_empty_space height=”20px”][vc_column_text]<\/p>\n
$2.5 Billion<\/h2>\n
Raised in Life Science Funds<\/strong><\/p>\n
<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1627536833709{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box capital-box box-hide” el_id=”solutions-capitals-box”]<\/p>\n
- \n
- Fund Trials (100%)<\/strong><\/li>\n
- Avoid Dilution<\/strong><\/li>\n
- Execute Large Deals<\/strong><\/li>\n
- Bridge To Readouts<\/strong><\/li>\n
- An Abingworth & Blackstone Company<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab expertise-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669659530{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”expertise” el_id=”expertise-blue-box”]<\/p>\n
Expertise<\/h2>\n
<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1620882992216{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box expertise-box box-hide” el_id=”solutions-expertise-box”]<\/p>\n
- \n
- Multiple Approvals<\/strong><\/li>\n
- US \/ Japan \/ China \/ EU<\/strong><\/li>\n
- Trial Design<\/strong><\/li>\n
- Trial Execution<\/strong><\/li>\n
- World-Class Advisors<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab resources-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1616669760758{padding-top: 20px !important;padding-bottom: 20px !important;background-color: #001e3c !important;}” el_class=”resources” el_id=”resources-blue-box”]<\/p>\n
Resources<\/h2>\n
<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625220589763{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box resources-box box-hide” el_id=”solutions-resources-box”]<\/p>\n
- \n
- Global Reach<\/strong><\/li>\n
- Multiple Disciplines<\/strong><\/li>\n
- Incremental Headcount<\/strong><\/li>\n
- CRO Management<\/strong><\/li>\n
- Full Service<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”faq-tab pipeline-solutions” width=”1\/4″][vc_column_text css=”.vc_custom_1625220577090{padding-top: 4px !important;padding-bottom: 3px !important;background-color: #001e3c !important;}” el_class=”pipeline” el_id=”pipeline-blue-box”]<\/p>\n
Pipeline \/ Asset Acceleration<\/h2>\n
<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625220681454{background-color: rgba(255,255,255,0.85) !important;*background-color: rgb(255,255,255) !important;}” el_class=”strategic-funding-section-box pipeline-box box-hide” el_id=”solutions-pipeline-box”]<\/p>\n
- \n
- New Indications<\/strong><\/li>\n
- Incremental Assets<\/strong><\/li>\n
- In-Licensing \/ M&A Support<\/strong><\/li>\n
- Augmented Trial Budget<\/strong><\/li>\n
- Parallel Trials (vs. Sequential)<\/strong><\/li>\n
- Ex-US Approvals<\/strong><\/li>\n<\/ul>\n
[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1628682735405{background: #ffffff url(https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2021\/05\/SFJ-by-the-numbers.jpg?id=8623) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” z_index=”” el_class=”sfj-numbers” background_image=”8154″][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_empty_space height=”20px”][\/vc_column_inner][\/vc_row_inner][vc_single_image image=”10788″ img_size=”full” alignment=”center” qode_css_animation=””][vc_empty_space height=”40px”][vc_empty_space height=”40px” el_class=”empty-space-home”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][qode_elements_holder number_of_columns=”two_columns” columns_proportion=”25_75″ switch_to_one_column=”never” alignment_one_column=”left”][qode_elements_holder_item vertical_alignment=”middle” horizontal_alignment=”center” advanced_animations=”no” item_padding=”0px 5px 0px 0px”][vc_single_image image=”11208″ img_size=”150 x 68″ alignment=”center” qode_css_animation=””][\/qode_elements_holder_item][qode_elements_holder_item vertical_alignment=”middle” advanced_animations=”no” custom_class=”sfj-bracket-text-right”][vc_column_text]<\/p>\n
- \n
- Fills operational and funding gaps<\/li>\n
- Provides bridge to increased ex-U.S. value<\/li>\n
- Assumes 100% of clinical development risk<\/li>\n
- Augments expertise<\/li>\n
- Accelerates follow-on indications<\/li>\n
- Tailors payback to financial objectives<\/li>\n<\/ul>\n
[\/vc_column_text][\/qode_elements_holder_item][\/qode_elements_holder][vc_empty_space height=”40px” el_class=”empty-space-home”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1625602041936{background-color: #ffffff !important;}” z_index=”” el_class=”sfj-numbers” background_image=”8154″][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]<\/p>\n
SFJ By The Numbers:<\/h2>\n
[\/vc_column_text][vc_separator type=”small” position=”center” width_in_percentages=”yes” color=”#fd5020″ transparency=”1″ thickness=”6″ width=”30″ up=”22″ down=”22″][vc_empty_space height=”40px”][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”” el_class=”sfj-numbers”][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Total Deal
\nValue<\/h3>\n[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
$4.5 billion<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Total # of
\nPartnerships<\/h3>\n[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
11<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
# of Oncology Partnerships<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
6<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Year
\nFounded<\/h3>\n[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
2009<\/h3>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text el_class=”sfj-text”]<\/p>\n
Major Market Approvals<\/h3>\n
[\/vc_column_text][vc_empty_space height=”10px”][vc_column_text el_class=”sfj-text-no”]<\/p>\n
17<\/h3>\n
[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”40px”][vc_empty_space height=”40px”][vc_row_inner row_type=”row” type=”grid” text_align=”center” css_animation=”” el_class=”mpb”][vc_column_inner el_class=”hide-col-btn” width=”1\/6″][\/vc_column_inner][vc_column_inner el_class=”bracket-top” width=”2\/3″ css=”.vc_custom_1629868834725{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column_text el_class=”bracket-bottom” css=”.vc_custom_1625154729407{padding-right: 30px !important;padding-bottom: 30px !important;padding-left: 30px !important;}”]<\/p>\n
\u201cSFJ has proven to be a collaborative and transparent partner from the start of our partnership.\u00a0 Their team is extremely knowledgeable, and add immense value well beyond the financial aspect.\u00a0 SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.\u201d<\/em><\/p>\n
<\/p>\n
\u2014 Cedric Francois, CEO<\/strong>
\nApellis Pharmaceuticals<\/p>\n[\/vc_column_text][vc_empty_space height=”40px” el_class=”empty-space-home”][\/vc_column_inner][vc_column_inner el_class=”hide-col-btn” width=”1\/6″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”center” background_image_as_pattern=”without_pattern” css=”.vc_custom_1629891940309{background: #ffffff url(https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2020\/12\/bg-image-2.jpg?id=1168) !important;}” z_index=”” el_class=”primary-investors”][vc_column css=”.vc_custom_1607517714812{padding-top: 100px !important;padding-bottom: 100px !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]<\/p>\n
Primary Investors<\/h2>\n
[\/vc_column_text][vc_separator type=”small” position=”center” width_in_percentages=”yes” color=”#fd5020″ transparency=”1″ thickness=”6″ width=”30″ up=”22″ down=”22″][vc_empty_space height=”40px”][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”grid” text_align=”center” css_animation=””][vc_column_inner width=”1\/4″][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_single_image image=”1133″ img_size=”full” style=”vc_box_shadow” onclick=”custom_link” img_link_target=”_blank” qode_css_animation=”” link=”https:\/\/www.blackstone.com”][vc_empty_space height=”20px”][vc_column_text]<\/p>\n
Over $800 Billion<\/h2>\n
Assets Under Management<\/strong><\/p>\n
[\/vc_column_text][vc_empty_space height=”10px”][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_single_image image=”1213″ img_size=”full” style=”vc_box_shadow” onclick=”custom_link” img_link_target=”_blank” qode_css_animation=”” link=”https:\/\/www.abingworth.com” el_class=”mpb”][vc_empty_space height=”20px”][vc_column_text]<\/p>\n
$2.5 Billion<\/h2>\n
Raised in Life Science Funds<\/strong><\/p>\n
- Incremental Assets<\/strong><\/li>\n
- Multiple Disciplines<\/strong><\/li>\n
- US \/ Japan \/ China \/ EU<\/strong><\/li>\n
- Avoid Dilution<\/strong><\/li>\n
![\"\"](\"https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2020\/12\/SFJ-asset-FDA-approval.png\")
<\/div>![\"\"](\"https:\/\/www.sfj-pharma.com\/wp-content\/uploads\/2021\/12\/checkm.png\")
<\/div>